Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

By sjmartinez • September 9, 2024

Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial. J Thorac Oncol. 2024 Sep 5:S1556-0864(24)02264-0. doi: 10.1016/j.jtho.2024.09.1381. Epub ahead of print. PMID: 39243945.

Tags: durvalumab, five-year overall survival, Hematology/Oncology, metastatic NSCLC, POSEIDON, Publications, tremelimumab

Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study

Valle LF, Chu FI, Wang X, Erman A, Hernandez J, Kaoh E, Edgar N, Raldow AC, Wong DJ, Steinberg ML, Kishan AU, Chin RK, Hegde[...]

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park[...]

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.[...]